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Positron emission tomography (PET) radiotracer develop-
ments over the past decade have enabled in vivo measure-
ment of amyloid-beta (Ab) plaque deposition, a key
neuropathological hallmark of Alzheimer’s disease (AD).
This presentation will provide an overview of the transla-
tional research path for one of the most widely used PET
Ab imaging agents, 11C-lableled Pittsburgh compound-B
([11C]PiB). Early preclinical ex-vivo characterization
revealed the capacity of [11C]PiB to bind to fibrillar Ab
plaques [1]. Real-time in vivo multiphoton microscopy
demonstrated that [11C]PiB labeled individual Ab plaques
in transgenic mouse models of AD [2]. Human proof-of-
concept studies then showed nearly 2-fold greater uptake
of [11C]PiB in AD patients relative to controls in areas of
brain known to contain amyloid in AD (frontal cortex,
p<0.0001), while retention was equivalent for both groups
in areas known to be relatively unaffected by amyloid
deposition (subcortical white matter, pons, cerebellum;
p>0.2) [3]. These semi-quantitative studies were followed
by fully quantitative arterial-based kinetic modeling
PET studies that supported the validity of simplified (non-
arterial) [11C]PiB PET retention outcomes that exhibited
good test-retest reliability (5-10%) needed for improved
study feasibility for clinical application on cross-sectional
and longitudinal bases [4] and for large collaborative
multi-site studies, such as the Alzheimer’s disease neuroi-
maging initiative (ADNI).
Early translational findings include cross-sectional evi-
dence of amyloid deposition (i.e., [11C]PiB retention) in
20-30% of cognitively normal elderly controls, variable
retention in subjects with mild cognitive impairment
(MCI) that ranged from negligible to AD-like levels and
additional findings in those at risk for the development of
AD [[5], for review]. Emerging longitudinal results indicate
small significant increases in [11C]PiB retention in AD and
MCI groups, and in controls who had high baseline reten-
tion [6]. Efforts are ongoing to establish relationships
between in vivo imaging measures and post-mortem mea-
sures of Ab deposition in those scanned with [11C]PiB
PET imaging before death. Anti-amyloid therapies have
shown promise based on [11C]PiB PET imaging results
in early treatment trials. Lastly, the development of
18F-labeled Ab imaging agents (several-fold longer radio-
active half-life than 11C) has allowed greater distribution
and translational capability, with one such agent recently
being approved by the U.S. Food and Drug Administration
for use in the rejection of AD diagnosis in patients under
evaluation for AD. A decade of translation has further
clarified the need for sensitive early detection of AD
pathophysiology in order to identify those who might ben-
efit most from future therapeutic intervention.
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